View Post

Amended Protocols Allow for Reduced GI Toxicities With Oral Paclitaxel Combo in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristie L. Kahl From: cancernetwork.com Allowing for the use of antiemetic prophylaxis and anti-diarrheal medication in the phase 3 KX-ORAX-001 study reduced study drug-related gastrointestinal adverse events. Following protocol amendments to the administration of oral paclitaxel plus encequidar, patients with metastatic breast cancer experienced fewer gastrointestinal (GI) adverse events (AEs), resulting in outcomes that were more in line with …

View Post

Research Moves Full Steam Ahead With Brain Metastases, Leptomeningeal Disease in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases and/or leptomeningeal disease. Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases …

View Post

Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Allarity Therapeutics on Thursday said that it has enrolled the first patient in a European Phase II clinical trial evaluating the microtubulin inhibitor ixabepilone (Ixempra) as a third-line treatment for certain metastatic breast cancers. Specifically, Allarity — previously named Oncology Venture — will evaluate the agent, a product for which it in-licensed the European rights …

View Post

Compound isolated from Moroccan fungus shows promise to fight triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Medical College of Georgia at Augusta University From: news-medical.net A compound isolated from a fungus growing on the roots of a flowering plant in Morocco shows promise as a powerful opponent of aggressive triple negative breast cancer, scientists say. They have early evidence that the peptide EnnA, isolated from a fungus living symbiotically with a flowering plant known for …

View Post

OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: finance.yahoo.com — TAVO intratumoral therapy was safe and effective at increasing tumor antigen specific presentation and recruitment of CD8+ T cells, indicating ability to generate robust anti-cancer immune response — — TAVO treatment-related CXCR3 gene signature associated with improved outcomes and conversion of non-responsive tumors; Future studies of TAVO with chemokines to assess anti-tumor immunity – OncoSec Medical Incorporated …

View Post

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease. The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast …

View Post

Tissue filler, scaffold technologies provide new options for patients with breast cancer, other diseases

In Clinical Studies News by Barbara Jacoby

By: Chris Adam, Purdue University From: medicalxpress.com New technology from Purdue University innovators may help improve tissue restoration outcomes for people with breast cancer and other diseases or traumatic injuries. Purdue researchers, along with fellowship-trained breast surgeon Carla Fisher of Indiana University School of Medicine, teamed up with Purdue startup GeniPhys to develop and perform preclinical studies on a regenerative …

View Post

Researchers find anti-stress drugs can stop breast cancer spreading

In Clinical Studies News by Barbara Jacoby

By: Hamish Goodall From: news.com.au Australian researchers have made a major medical breakthrough that could extend the lives of people battling breast cancer. Scientists at Monash University have found that everyday anti-stress drugs, called beta blockers, could slow the spread of the deadly disease in the body. Associate Professor Erica Sloan said the research team made the discovery after identifying …

View Post

IU School of Medicine scientists discover ‘game-changer’ treatment for triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

From: miragenews.com A team of Indiana University School of Medicine researchers has developed a novel antibody-drug conjugate for treating triple negative breast cancer. The study, led by senior author Xiongbin Lu, Vera Bradley Foundation Professor of Breast Cancer Innovation at the IU School of Medicine, has been published in the prestigious interdisciplinary medical journal, Science Translational Medicine. Triple negative breast …

View Post

Using artificial intelligence to hunt for breast cancer

In Clinical Studies News by Barbara Jacoby

By: BfR Federal Institute for Risk Assessment From: medicalxpress.com Endocrine disruptors (EDs) are hormone-like substances that can have undesirable effects on health. For example, chemicals can increase the risk of breast cancer if they act in a manner similar to the female sex hormone estrogen. Animal experiments are still required to detect the hormonal effects of chemical substances. A test …